Login to Your Account



Cephalon Filing Supplemental NDA For New Sleep Disorders

By Randall Osborne


Thursday, December 26, 2002
As generic competition looms for its narcolepsy tablet Provigil, Cephalon Inc. said it has filed a supplemental new drug application seeking a broadened label that would include other sleep and wakefulness disorders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription